Indogulf Cropsciences Ltd
Indogulf Cropsciences Ltd Q1 FY27 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY27 earnings call: what management guided on revenue, margins and order book.
The short version
The company grew topline by around 19% in FY26 and is targeting good growth in FY27, though no specific growth guidance was committed due to industry uncertainties. - With existing capacity, peak revenue can reach Rs. Indogulf expects sustained top-line and bottom-line growth over the medium to long term, driven by product mix improvement and higher margin specialty products like biologicals and plant nutrition.
From Indogulf Cropsciences Ltd's Q1 FY27 earnings-call transcript · updated 18 Sept 2026.
Revenue & Sales Performance
- The company grew topline by around 19% in FY26 and is targeting good growth in FY27, though no specific growth guidance was committed due to industry uncertainties.
- With existing capacity, peak revenue can reach Rs. 1100-1200 crores; with expanded capacity, turnover can target Rs. 1800+ crores within 2-3 years.
- Management focuses on expanding high-margin product mix, including biologicals and plant nutrition, which grew from 11% to 22% of brand sales recently.
- International expansion is ongoing with registrations in various countries (e.g., Taiwan, Sri Lanka, Saudi Arabia) to add new markets.
- The company is investing in backward integration, manufacturing efficiency, and working capital optimization to support margin and volume growth.
- Growth is anticipated to be driven by sustainable solutions, innovation (e.g., heat and drought-resistant crops), and enhanced farmer engagement.
- External factors like El Nino and delayed monsoon create near-term uncertainties but are considered time-related rather than structural.
Profitability & Margins
See what Indogulf Cropsciences Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Indogulf Cropsciences is continuing to invest in manufacturing infrastructure, including:
- - Expansion at the Barwasni plant.
- - Development of a new Dry Formulation (DF) manufacturing facility.
- Capital work-in-progress stood at Rs. 76.4 crores in FY26, up from Rs. 57.1 crores in FY25, reflecting ongoing investments.
- The company’s capacity utilization increased to 70% in Q1 FY27 with the current expanded capacity capable of supporting a top line of around Rs. 1800 crores over the next few years.
- Growth-focused investments include product development, distribution network expansion, and export capabilities to build a stronger platform for medium-to-long-term growth.
- Innovation and collaboration with ICAR-IARI on next-generation crop solutions are central, focusing on producing heat-resistant and drought-tolerant products.
- No immediate plans for new capacity beyond current expansions; current investments expected to support growth for 2-3 years.
Top-ranked in Fertilizers & Agrochemicals
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Indogulf Cropsciences Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
Indogulf Cropsciences Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹109 Cr, net profit ₹4 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Indogulf Cropsciences Ltd's management said in earlier quarters
Others in Fertilizers & Agrochemicals this season
- Gujarat State Fertilizers & Chemicals Ltd (Q1 FY27)
Profit after tax increased by 15% YoY in Q1 FY27, signaling positive growth trajectory. Key concall takeaways from Gujarat State Fertilizers & Chemicals Ltd's…
- GSP Crop Science Ltd (Q1 FY27)
Capacity utilization indicates room for growth: 70-75% for technical and 25-30% for formulations. Key concall takeaways from GSP Crop Science Ltd's Q1 FY27…
- Rallis India Ltd (Q1 FY27)
. Key concall takeaways from Rallis India's Q1 FY27 earnings call — and how it ranks against sector peers.
- Coromandel International Ltd (Q1 FY27)
Specialty Nutrient business growing consistently at 25%-30% with high EBITDA margins (~20%). Key concall takeaways from Coromandel Inter's Q1 FY27 earnings…
Frequently Asked Questions
What were Indogulf Cropsciences Ltd Q1 FY27 results?
The company grew topline by around 19% in FY26 and is targeting good growth in FY27, though no specific growth guidance was committed due to industry uncertainties. - With existing capacity, peak revenue can reach Rs. Indogulf expects sustained top-line and bottom-line growth over the medium to long term, driven by product mix improvement and higher margin specialty products like biologicals and plant nutrition.
What is Indogulf Cropsciences Ltd share price analysis?
Indogulf Cropsciences Ltd currently shows a neutral. The stock trades at a P/E of 11.1 with a market cap of ₹427 Cr. Investors should review the full earnings analysis for detailed insights.
Is Indogulf Cropsciences Ltd planning capital expenditure?
Indogulf Cropsciences is continuing to invest in manufacturing infrastructure, including: - Expansion at the Barwasni plant. - Development of a new Dry Formulation (DF) manufacturing facility. - Capital work-in-progress stood at Rs.
Keep Indogulf Cropsciences Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.
